Stockreport

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma

Bristol-Myers Squibb Company  (BMY) 
Last bristol-myers squibb company earnings: 2/6 07:05 am Check Earnings Report
US:NYSE Investor Relations: bms.com/investors.html
PDF Iberdomide has the potential to be the first approved CELMoD agentThe U.S. FDA has granted Breakthrough Therapy Designation and Priority Review for this indication and a [Read more]